I Was “Metabolically Healthy.” I Got a Stent at 44 Anyway.

By the rules I’d been taught, I was the safe candidate.

Low hsCRP. Low A1c. Flat CGM. No insulin resistance. Lp(a) not elevated. Thirty years of training. The word from the world of podcasts was that LDL doesn’t matter if your metabolic markers look like that. Mine were pristine.

Then a CT angiogram found an 80% blockage in my right coronary artery. At 44.

Here’s what they don’t tell you: “metabolically healthy” isn’t a diagnosis. It’s a claim, one that rests on assumptions about your inflammation, your endothelium, and your genetics that you’ve never actually verified.

I hadn’t. I couldn’t find a cardiologist who’d run the tests that would have told me. And I’m a clinician-scientist who was working in the ER at Mayo Clinic, with access to the best care in the world.

The Bottom Line “Metabolically healthy” is a claim about you, not a diagnosis. It rests on four assumptions about your inflammation, blood pressure, autoimmune status, and genetics that almost no one verifies. I had a perfect metabolic panel and an 80% coronary blockage anyway. The framework wasn’t wrong for everyone. It was wrong about its ability to tell me whether I was one of the people it worked for.

Vocabulary that matters

• Metabolically healthy: shorthand for normal glucose, insulin sensitivity, triglycerides, blood pressure, and inflammatory markers. Useful, but it is not a picture of your coronary arteries.
• LDL-C: the standard cholesterol number on a routine panel: the mass of cholesterol your LDL particles carry.
• ApoB: a count of the actual particles. One ApoB per particle, and particles are what lodge in the artery wall. When it disagrees with LDL-C, risk follows ApoB.
• hsCRP: a blood marker of systemic inflammation. Useful, but blind to inflammation down at the artery wall.
• Lp(a): a genetically-set lipoprotein that can be more artery-damaging than ordinary LDL. Most people are never tested.
• Endothelium: the thin living lining inside every artery. Where plaque starts, and where blood pressure does its daily damage.

The framework I trusted

After the stent, I did what I should have done years earlier. I stopped outsourcing my risk model to podcasts and went back to the primary literature myself. I started to apply the same standard I learned in cancer epigenetics and building bioinformatics pipelines at the bench.

I needed to understand what I had actually been believing. Because it wasn’t vague. It was a framework. It had rules. And I had been applying it to my own body for close to a decade.

Here’s the framework, in the words I would have used at the time:

If your hsCRP is low and your metabolic markers are clean (fasting glucose, HbA1c, fasting insulin, a CGM that stays nearly flat), then elevated LDL on a high-fat diet is metabolically benign. The cholesterol-heart hypothesis was built on the wrong population. Eat the steak. Eat the eggs. Don’t worry about the LDL number.

That’s the keto and carnivore community’s argument in one paragraph. It’s not a strawman. It’s how I heard it on podcasts week after week, and it’s how I repeated it to myself when my LDL crept into the 150s and 160s.

So here’s my scorecard against that framework, somewhere around 2018 to 2023:

• hsCRP: 0.45 mg/L. Textbook low.
• HbA1c: low 5s and steady for many years.
• Fasting glucose: unremarkable.
• Continuous glucose monitor: I wore one for several stretches. Flat. No concerning spikes.
• Insulin resistance: none, confirmed by labs and CGM.
• Lp(a): not an issue. This is a genetically-determined lipoprotein that can be more atherogenic than standard LDL.
• Lean. Trained. Thirty years of consistent exercise.

By the framework’s own rules, I was the safe candidate. The poster child. If keto was going to work for anyone, it was going to work for me.

But it didn’t. And when I went back to the papers (the actual papers, not the Twitter threads summarizing them), I found out that the framework was silent on a lot of things it should have told me it was assuming.

Why LDL matters anyway

The cumulative exposure problem

As I walked through a few weeks ago in my takedown of the retracted KETO trial, the framework treats LDL as a snapshot. Your LDL is 145 today. It’s fine today. Move on.

That’s not how LDL damages an artery. High LDL accumulates in and contributes to damage of an artery over years. The longer you carry an elevated LDL, the more ApoB-containing particles have lodged in your arterial wall and initiated the processes that build plaque. A single snapshot at age 40 doesn’t capture what twenty years of moderate elevation has been doing.

A 2015 Circulation study led by Ann Marie Navar-Boggan looked at young adults with prolonged moderate hyperlipidemia and followed their long-term coronary risk¹. The signal was clear: even at levels that wouldn’t trigger a statin prescription under conventional thresholds, prolonged exposure in young adulthood translated into substantially elevated mid-life risk. The math is straightforward. LDL damages the artery each year it’s elevated. Ten years of LDL 145 is not the same exposure as one year of LDL 145. It’s ten times the exposure.

And the genetics back that up causally, not just epidemiologically. A 2012 Mendelian randomization study in JACC by Brian Ference and colleagues used naturally occurring genetic variants that lower LDL from birth to estimate the effect of lifelong lower exposure². The finding: people who carry LDL-lowering variants from birth get roughly a threefold greater reduction in risk, for the same drop in LDL, than people who start a statin in middle age. The difference isn’t the drug. The difference is the duration.

So when a health and fitness influencer tells you LDL 145 is fine because you’re metabolically healthy, they’re telling you about today. They’re not telling you about the 3,600 days you just spent with LDL particles crossing your endothelium. Ten years of particles slipping through a door I’d been told was locked. The cumulative exposure is the damage. Metabolic health doesn’t pause the clock.

I would guess that I spent at least fifteen years with LDL between 130 and 160. Possibly longer. It’s something I never even had checked until I was around 30, and it was slightly elevated even then. If it was mildly elevated at 30, it could have been mildly elevated since adolescence. That’s an unknown, because teenagers typically don’t get a cholesterol test. So the fitness-influencer framework was telling me I was fine. The genetics and the epidemiology say otherwise.

The Read A clean panel describes today. It says nothing about the years of ApoB particles already lodged in my artery wall. Duration is the dose, and there’s no metabolic-health override for it.

The particle-count problem

Here’s the other thing the snapshot doesn’t capture. LDL-C is a measurement of the mass of cholesterol carried in LDL particles. ApoB is a measurement of the number of LDL particles. Those two numbers are correlated most of the time. But they’re not the same thing, and when they disagree (when they’re “discordant,” in the lipidology vocabulary), risk tracks with ApoB, not with LDL-C³.

Why? Because what actually damages an artery is the particles that cross the endothelial wall and get trapped there, not the cholesterol cargo they’re carrying. Each LDL particle has one ApoB molecule on its surface. One particle, one ApoB. So total ApoB tells you exactly how many of these dangerous little parcels are circulating. LDL-C tells you how much cholesterol is packed into them on average, and that average varies considerably person to person.

The practical upshot: it is possible to have “mildly elevated” LDL-C and a high ApoB. You can be the “metabolically healthy” patient whose standard lipid panel gets you waved through, while running a particle count that looks like someone on the way to a cath lab. The framework doesn’t know the difference. Your doctor probably didn’t order ApoB. You probably don’t know to ask, and therefore don’t know this number.

I didn’t. Not until after the stent.

The diet-shapes-the-picture problem

And finally, the population data. A 2018 Lancet Public Health study led by Sara Seidelmann pooled data from 432,179 people across eight multinational cohorts and found a U-shaped relationship between carbohydrate intake and all-cause mortality⁴. Lowest mortality sat around 50–55% of energy from carbs. Both very low-carb and very high-carb diets carried increased mortality.

But here’s the part the framework can’t explain away. The substitution finding. When people achieved a low-carb diet by replacing carbs with animal-based fat and protein, the pooled hazard ratio for mortality was 1.18 (95% CI 1.08–1.29), about 18% higher. When they achieved the same low-carb intake with plant-based fat and protein, the hazard ratio was 0.82 (95% CI 0.78–0.87), about 18% lower. Same carb percentage. Opposite direction. The macronutrients you swap in matter.

The diet I did for ten years was the animal-source version. I was sitting on the wrong end of that U-curve, in the wrong substitution subgroup, and the framework I trusted was telling me it didn’t matter because my HbA1c was clean and I had zero systemic inflammation.

This doesn’t prove the animal-heavy version of low-carb caused my blockage. It’s observational data, built from self-reported diet, and I won’t pretend it can answer a personal causation question that precisely. But it breaks the lazy version of the argument. “Low carb” isn’t one biological exposure. A diet built on olive oil, nuts, fish, and plants isn’t the same exposure as one built on steak, eggs, and butter, even when the carbohydrate percentage is identical on paper. The U-curve held across eight cohorts, about as consistent as observational nutrition data gets. Same macro label. Different biology.

What “metabolically healthy” isn’t telling you

Here’s where it gets uncomfortable. “Metabolically healthy” is a claim about you, and like any claim, it rests on assumptions. The framework doesn’t tell you what it’s assuming. It just hands you the rule and assumes you fit.

The assumptions the framework is making, most of the time quietly, are these:

It’s assuming you don’t have tissue-level inflammation your hsCRP can’t see. hsCRP measures systemic, blood-level inflammation. It’s useful. It’s not a window into your arterial wall. The inflammation that drives plaque progression lives at the lesion: local, often quiet at the systemic level, sometimes invisible on any blood test you’d normally run. My hsCRP was 0.45. The 0.45 was real. It just wasn’t measuring the thing I needed it to measure. I’ll come back to localized inflammation at the arterial wall versus the systemic kind in a dedicated post. They’re two different animals.

It’s assuming your blood pressure is actually optimal, not just “not medication territory.” A BP in the low 130s over mid-80s is the kind of number most doctors don’t treat. It’s not a disease. It’s also not ideal. Borderline-elevated blood pressure hits your endothelium, the inner lining of your arteries, every single day, subtly, cumulatively. A dedicated post on this is now live, because “not horrible” is not the same as “fine.”

It’s assuming you don’t have an undiagnosed autoimmune or inflammatory condition quietly driving vascular damage. There are a number of conditions that share molecular machinery with atherosclerosis and accelerate plaque progression through inflammatory pathways, sometimes even the mild, quiet versions of them that a patient has ignored for years because they’re “just a skin thing” or “just a joint thing.” I had one of those for most of my adult life. I had a category for it: cosmetic. I did not have a category for this might be talking to my coronaries. No physician ever offered me one. The framework assumed there was nothing here. I’m working through that piece of the story now, and will share the results with you as I keep traversing this journey of how I went from clean arteries at 36 to on my way to a heart attack at 44.

It’s assuming your genetic endothelial signaling is generic and unremarkable. There are variants in vascular signaling pathways that change how your arteries respond to stress: how they relax, how they repair, how they handle the daily insult of a little too much LDL and a little too much pressure. Most people have never had these evaluated. Most physicians don’t order the panel. Mine isn’t unremarkable. I didn’t know that until 2026. We’ll come back to this one later, and when we do, we’re going to talk about some specific things that changed for me once I understood what my genetics were actually doing at a molecular level.

Each of these assumptions, when it fails, makes LDL more dangerous, not less. The framework treats them as neutral or absent. They rarely are. And the kicker is that the people most confident in the framework, the people telling you your LDL is fine, sometimes haven’t even verified these assumptions in themselves either.

The Read “Metabolically healthy” measured the things that were fine and stayed silent on the things that weren’t. A normal panel is real information about a narrow question, not a clean bill of health for your arteries.

I came to this through cancer biology

I take epigenetic clocks seriously, and I also know exactly what they can’t see, because before any of this I was at the bench studying the epigenetics of cancer. My work was on melanoma: when you hit a BRAF-mutant tumor with a targeted drug, the cells that survive rewrite their histone methylation, the chemical marks on the proteins your DNA is wound around, to escape it. I extracted tumors and ran the mass spectrometry myself, watching marks like H3K27 lose methylation as the cancer learned to resist⁵.

That is the same class of machinery aging science now runs on. Epigenetic clocks read a different layer: DNA methylation, the marks on the DNA itself rather than on the histones. But it’s the same story I watched in cancer, the epigenome drifting off its program. Epigenetic dysregulation is one of the core drivers of biological aging, and an accelerated epigenetic age tracks metabolic dysfunction and predicts death⁶. I didn’t wander into this field because I got a stent. It’s the biology I was trained in, turned toward a new question.

Which is exactly why the next part bothers me. An epigenetic clock reads your whole-body epigenetic state, and it tracks the same metabolic and lifestyle inputs that were clean on my panel. A lean, well-trained person with a flat CGM scores young on it. So the most sophisticated aging test we have would have done what my hsCRP did: handed me a reassuring number while a soft plaque built in an artery it never looks at. It measures the system. It is not a camera pointed at your coronary wall. That gap, systemic versus local, is the thread I’ll keep pulling in the posts ahead.

My landing

I had every marker in the influencer framework’s safe column. I also had enough hidden risk signals sitting outside that framework to stop treating it as a safety certificate. The framework wasn’t wrong for everybody. Some people do phenomenally well on ketogenic and carnivore diets. But the framework is silent about who it is wrong for.

That’s the actual problem. It’s not that keto is a killer. It’s not that high-fat diets are evil. It’s that the framework assumes a clean endothelium, a clean particle count, a clean inflammatory picture, and a clean genetic background. And it asks you to assume the same about yourself without ever verifying any of it. I work in the ER. I read the primary literature. I spent fifteen years in the health-and-wellness industry before that. I had access most patients never get. And I still didn’t know I checked any of those boxes until the diagnosis had already been made.

If I couldn’t see it (with the training, the access, the proximity to the literature), what chance does a 38-year-old with a podcast subscription have? That’s why I’m telling this story.

That’s the argument. I’m not telling you the diet by itself caused my stent. I don’t have the evidence to say that, and I don’t think any one thing is to blame. Like many things in life, it’s the combination of unknown things that all come together at the worst of times that leads to these horrible health outcomes. What I am telling you is that the framework I trusted assumed things about me that turned out not to be true, and the population-level data was pointing at the wrong end of a curve I was sitting on. At best, the diet wasn’t helping me. At worst, it was a likely contributor to what happened. That’s the most honest thing I can say about it.

What I changed, and what I didn’t

I’m not on keto anymore. Not on carnivore. Not “carnivore-light.”

I eat more fruits and veggies now, although the latter still isn’t my favorite. I still eat steak (I love steak), but it’s no longer the architecture of the diet. Vegetables carry more of the volume. Fiber is back. I’m not prescribing you a meal plan. I’m telling you what I changed and why. After all the research I did, if I had to pick one label for what I now do, it would be closest to the Mediterranean diet.

What I’m not going to do in my newsletter or any single post is give you macros, hand you a protocol, or pretend the diet alone explains the stent. Instead, what I will be doing is just taking you along for the journey I’ve been on for the last year. One that zigs and zags between genetics, diet, biohacking devices and routines, exercise, and a lot of peer-reviewed evidence, with the goal of helping me determine what almost caused a heart attack.

The diet was one crack of several I’m still walking through. It’s the one I had the most control over and the one I had the most confidence about. And the confidence was the problem.

The Final Signal

• What the framework gets right. Some people genuinely thrive on low-carb and keto, and a clean metabolic panel is real, useful information. “Metabolically healthy” isn’t a lie.
• What it overstates. That a clean panel makes elevated LDL benign for you. It can’t tell you that. It’s silent on cumulative exposure, particle count, and the assumptions it quietly makes about your arteries.
• What I changed. Off carnivore and keto. Steak’s still there; vegetables and fiber carry the volume now. The closest label for where I landed is Mediterranean.
• What would change my mind. A long-term cohort of lean, metabolically-healthy people on high-LDL ketogenic diets with hard cardiovascular outcomes at or below the general population. Or a mechanism showing ApoB particles fail to interact with the endothelium in that phenotype. Neither exists yet.
• What’s next. Before the four hidden assumptions each get their own post, one more chapter on LDL itself: what “borderline” actually means over twenty years.

References

1. Navar-Boggan AM, Peterson ED, D’Agostino RB Sr, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131(5):451-458. PMID: 25623155
2. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639. PMID: 23083789
3. Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk. J Am Heart Assoc. 2022;11(20):e025858. PMID: 36216435
4. Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. 2018;3(9):e419-e428. PMID: 30122560
5. Grigore F, Yang H, Hanson ND, et al. BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. Neoplasia. 2020;22(9):376-389. PMID: 32629178
6. Wu S, et al. Impact of DNA-methylation age acceleration on long-term mortality among US adults with cardiovascular-kidney-metabolic syndrome. J Am Heart Assoc. 2025;14(7):e039751. PMID: 40118808